Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
3.09 ^USD	-1.90%		+0.65%	-6.93%

May. 10	Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting	CI
May. 09	Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 16, 2023 at 07:31 am EDT

Century Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 130.93 million compared to USD 95.82 million a year ago. Basic loss per share from continuing operations was USD 2.27 compared to USD 2.96 a year ago.

Diluted loss per share from continuing operations was USD 2.27 compared to USD 2.96 a year ago.

Latest news about Century Therapeutics, Inc.

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting	May. 10	CI
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating	Apr. 12	MT
Syncona agrees to sell stake in investee company for GBP7.4 million	Apr. 11	AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics	Apr. 11	MT
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101	Apr. 11	CI
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..	Apr. 10	CI
Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors	Apr. 10	CI
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.	Apr. 10	CI
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting	Apr. 09	CI
Canaccord Genuity Adjusts Price Target on Century Therapeutics to $24 From $22, Maintains Buy Rating	Mar. 15	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 14	MT
Century Therapeutics Shares Fall After Wider Loss, Lower Revenue in 2023	Mar. 14	MT
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Century Therapeutics, Inc. Announces CFO Changes	Jan. 19	CI
Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits	Dec. 09	CI
Century Therapeutics Gets FDA Clearance for Phase 1 Trial of Potential Systemic Lupus Therapy	Dec. 06	MT
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus	Dec. 06	CI
Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Century Therapeutics, Inc. and FUJIFILM Cellular Dynamics Enter into a Worldwide License Agreement	Nov. 09	CI
Century Therapeutics, Inc. Announces Chief Executive Officer Changes	Nov. 09	CI
Century Therapeutics, Inc. Announces Management Changes	Nov. 09	CI
Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Investors Look -2-	23-08-29	DJ

Chart Century Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Companyâs product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Century Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.15 USD

Average target price

14.17 USD

Spread / Average Target

+349.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CENTURY THERAPEUTICS, INC.	-6.93%	261M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research